AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Xencor to Participate in Upcoming Investor Conferences

April 1, 2019

MONROVIA, Calif.--(BUSINESS WIRE)--Apr 1, 2019--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that company management will participate in two upcoming conferences:

  • Jefferies 6 th Annual IO Cell Therapy Summit
    Date: Friday, April 5, 2019
    Location: Boston, MA
  • 18 th Annual Needham Healthcare Conference
    Date: Tuesday, April 9, 2019
    Presentation Time: 2:10 p.m. ET
    Location: New York, NY

A live webcast of the Needham Healthcare Conference presentation will be available under “Events & Presentations” in the Investors section of the Company’s website located at https://investors.xencor.com/events.cfm. A replay of the event will be posted on the Xencor website approximately one hour after the live event and will be available for 90 days following the event.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases. Currently, 12 candidates engineered with Xencor’s XmAb ® technology are in clinical development internally and with partners. Xencor’s XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit  www.xencor.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190401005858/en/

CONTACT: Charles Liles

626-737-8118

cliles@xencor.comMedia Contact

Jason I. Spark

Canale Communications

619-849-6005

jason@canalecomm.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS NEW YORK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL

SOURCE: Xencor, Inc.

Copyright Business Wire 2019.

PUB: 04/01/2019 04:05 PM/DISC: 04/01/2019 04:05 PM

http://www.businesswire.com/news/home/20190401005858/en